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Many cancers demonstrate metabolic transformation, configuring cellular metabolism to 
support malignant growth [1]. Metabolic patterns commonly observed in cancer include 
increased lipogenesis [2–4] and aerobic glycolysis, the metabolism of glucose to lactate, 
despite the availability of oxygen for oxidative phosphorylation [5, 6]. Up-regulation of 
aerobic glycolysis in cancer is known as the Warburg effect and is understood to be a 
malignant adaptation that allows continued proliferation in diverse microenvironments. The 
importance of metabolic transformation to cancer pathogenesis, however, raises important 
questions: Are these metabolic programs unique to cancer cells? If not, what might be their 
physiologic origins? Recent studies of postnatal neurogenesis have identified a physiological 
role in neural development for metabolic patterns typically associated with cancer, including 
both increased lipogenesis [7, 8] and aerobic glycolysis [8, 9]. In contrast to the production 
of aberrant onco-metabolites such as 2-hydroxyglutarate, which requires IDH mutation [10–
12], the lipogenic and glycolytic phenotypes frequently observed in cancer originate in the 
normal metabolic repertoire of neural progenitor cells. Neurogenesis, like cancer, involves 
rapid proliferation and these studies show that metabolic pathways in neural progenitors, as 
in cancer cells, are optimized for cell division. The pattern of increased lipogenesis and 
aerobic glycolysis manifest neural progenitors, is maintained in the progenitor-derived brain 
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tumor medulloblastoma; in this cancer, developmentally-regulated metabolism is co-opted 
to support malignant growth. These studies provide a developmental perspective on the 
origins of cancer cell metabolism.
Medulloblastoma is the most common malignant brain tumor in children, and presents an 
ideal opportunity to examine cancer arising as a disruption of developmentally-regulated 
growth [13]. Medulloblastomas originate from the cerebellum, which is the most prominent 
site of neural progenitor proliferation in early post-natal life. Several lines of evidence link 
cerebellar neural progenitor proliferation to medulloblastoma pathogenesis. In the first year 
of life in humans, or the first 15 days of life in mice, cerebellar granule neuron progenitors 
(CGNPs) proliferate in a germinal matrix along the outside of the cerebellum called the 
external granule cell layer (EGL). This period of rapid proliferation is triggered by 
activation of the Sonic Hedgehog (Shh) signaling pathway [14]. While proliferation of 
cerebellar progenitors is virtually shut down once cerebellar development is complete, 
mutations in humans that aberrantly activate the Shh pathway predispose individuals to 
medulloblastoma formation; importantly, this process is recapitulated in transgenic mice 
[15–17]. Thus mice with conditional deletion of Patched (Ptc) or constitutively active alleles 
of Smoothened (Smo) allow the process of medulloblastoma tumorigenesis process to be 
examined prospectively, from CGNP proliferation forward to cancer [17, 18].
Along with induction of proliferation in the postnatal cerebellum, Shh signaling induces 
characteristic metabolic patterns in CGNPs, including decreased fatty acid oxidation [7], 
increased lipogenesis [7] and aerobic glycolysis [8, 9]. Despite the normoxic environment of 
the postnatal brain, Shh drives a shift in energy production away from oxidative reactions. 
This developmentally-programmed metabolic configuration of CGNPs persists in primary 
medulloblastoma in transgenic mice [7–9]. Studies of human patients, moreover, show that 
the glycolytic phenotype of the model is shared by the actual disease; medulloblastomas are 
readily detected by clinical 18FDG-PET studies [19, 20] and glucose uptake correlates 
inversely with patient survival [19]. Thus understanding the cellular and molecular 
mechanisms of metabolic configuration of neural progenitors places the metabolic patterns 
of medulloblastoma into a developmental context and may provide key insight in tumor 
pathogenesis.
Bhatia et al demonstrated that Shh induced a metabolic switch from lipid consumption to 
lipid production [7]. After observing abundant lipid deposition in Shh-driven 
medulloblastomas in transgenic mice, the investigators examined whether fatty acid 
metabolism was altered by Shh in CGNPs, the normal cells from which these tumors 
originate. Bhatia et al found that CGNPs explanted into media containing Shh up-regulated 
key lipid synthesis enzymes, including Fatty Acid Synthase (FASN) and Acetyl-CoA 
Carboxylase (Acc1). Shh also caused down-regulation of enzymes required for lipid 
catabolism, including Acyl-CoA Oxidase 1 (Acox1) and Medium Chain Acyl-CoA 
Dehydrogenase (MCAD) [7]. These transcriptional changes seemed to be coupled with 
proliferation as they depended on the activity of the Rb-E2F axis; E2F1 knockdown blocked 
the induction of FASN and the suppression MCAD in Shh-treated CGNPs. Direct 
measurement of palmitate oxidation demonstrated that these transcriptional changes potently 
altered lipid metabolism; Shh reduced palmitate oxidation, which could be restored by the 
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subsequent addition of E2F1 shRNA. Thus, as depicted in Figure 1, Shh shifted the lipid 
metabolism of CGNPs from catabolic to synthetic, and this shift was mediated by E2F1 and 
negatively regulated by Rb [7].
Importantly, this metabolic switch was maintained in medulloblastoma, where it promoted 
tumor growth [7]. Treatment of medulloblastoma-bearing mice with inhibitors of either 
FASN or the CDK-Rb-E2F signaling pathway slowed medulloblastoma progression and 
prolonged mouse survival. Bhatia et al used the transgenic ND2:SmoA1 mouse line to 
generate animals with primary medulloblastoma. After tumor formation, these mice were 
injected daily for 2 weeks with either the CDK inhibitor olomoucine or with the FASN 
inhibitor C75. Both agents significantly extended animal survival by slowing tumor growth. 
Within treated tumors, C75 reduced lipid synthesis as expected. Similarly, olomoucine 
reduced intratumoral abundance of FASN [7]. Thus, direct inhibition of fatty acid synthesis 
exerted a significant anti-tumor effect and this effect was duplicated through CDK 
inhibition. Together these data show that lipogenic metabolism is both essential to tumor 
growth and derives from developmental physiology [7].
The same group, in a follow up investigation, demonstrated that the metabolic regulator, 
Peroxisome Proliferator-Activated Receptor-γ (PPARγ) plays a key role in shaping the 
metabolic response of CGNPs to Shh stimulation in a manner that persists after 
medulloblastoma formation [8]. The investigators show that E2F1 up-regulates PPARγ and 
that PPARγ in turn causes up-regulation of key glycolytic enzymes, Hexokinase 2 (Hk2) and 
Pyruvate Kinase M2 (PkM2), and of the glucose transporter Glut4. Inhibiting PPARγ in 
medulloblastoma-bearing ND2:SmoA1 mice decreased the expression of both Hk2 and 
PkM2, and reduced tumor glucose uptake, measured in vivo by 18FDG-PET scan. Similar to 
the inhibition of CDK and FASN, PPARγ inhibition reduced the rate of tumor growth and 
extended survival [8]. These findings further demonstrate that the proliferative and 
metabolic functions of neural progenitors are interconnected and jointly become subverted 
in medulloblastoma tumorigenesis. Moreover, as shown in Figure 1, this investigation 
demonstrates that changes in lipid and carbohydrate metabolizing enyzmes occur in concert, 
jointly regulated by common intracellular signals.
A non-biased metabolomic analysis determined the functional significance of Shh-mediated 
changes in the expression of metabolic enzymes. CGNPs were explanted into media with or 
without Shh and changes in media metabolite concentrations were measured over time. Shh 
increased lactate production and glucose utilization of CGNPs, without causing additional 
changes in nutrient utilization and metabolite production. Continuous, real-time 
measurement of media oxygen content showed that Shh did not increase the CGNP oxygen 
consumption rate, and that Shh-treated CGNPs retained significant unused capacity for 
mitochondrial respiration. In vivo studies, including quantitative measurement of 18FDG 
uptake and MR spectroscopy, further showed that glucose utilization and lactate production 
in the cerebellum were highest during the period of CGNP proliferation. 18FDG-PET also 
demonstrated that the glycolytic phenotype of CGNPs is preserved in ND2:SmoA1 
medulloblastoma. These studies confirmed that Shh signaling increased aerobic glycolysis in 
CGNPs and that Shh-driven medulloblastomas inherited the metabolic phenotype of their 
progenitor cells of origin [9].
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Importantly, these studies revealed that hexokinase isoforms Hk1 and Hk2 were expressed 
in mutually exclusive domains in the postnatal brain, defined by the presence or absence of 
proliferating progenitors. While proliferating CGNPs up-regulated Hk2, Hk1 was expressed 
by differentiated neurons throughout the brain. Hk1 was notably absent from the sites of 
postnatal progenitor proliferation, including the hippocampus, the subventricular zone, and 
the external granule layer of the cerebellum, the site of CGNP proliferation. These non-
overlapping patterns suggested that the selective expression of Hk2, rather than Hk1, was 
integral to neural progenitor proliferation [9].
Insight into the functional significance of Hk2 expression in neural progenitors came from 
studies that conditionally deleted Hk2 in the brain. Mice with a floxed allele of Hk2 (Hk2f/f) 
were crossed with hGFAP-cre mice that express cre recombinase in brain stem cells during 
early brain development. While HK2 was deleted throughout the cerebellum, only CGNPs 
were directly affected because CGNPs are the primary source of Hk2 in the postnatal 
cerebellum [21]. Metabolomic analysis showed that CGNPs in hGFAP-cre;Hk2f/f mice 
generated markedly less lactate when exposed to Shh, confirming that Hk2 deletion blocked 
the induction of aerobic glycolysis by Shh [9].
Genetic deletion of Hk2 enabled functional studies to determine the role of aerobic 
glycolysis in both CGNP development and medulloblastoma tumorigenesis. Mice with 
conditional deletion of Hk2 were viable and fertile and had no overt neurologic deficits. 
Inspection of the cerebellar microanatomy, however, revealed disruption of the typically 
regular pattern of cell layering, and increased capillary formation disrupting the EGL. 
CGNPs typically migrate along a predictable route as they differentiate into neurons; in 
focal areas, Hk2-deficient CGNPs differentiated without completing migration, resulting in 
granule neurons positioned aberrantly on both sides of the Purkinje cell layer. The increased 
vascularity of the cerebellum in hGFAP-cre;Hk2 f/f mice suggested that Hk2-deficient 
CGNPs were increasingly dependent on oxidative metabolism and local tissue oxygenation, 
while the aberrant migration suggested disrupted timing of CGNP differentiation.
Further evidence that aerobic glycolysis negatively regulates terminal differentiation came 
from conditional deletion of Hk2 in medulloblastoma-prone mice. These mice were 
generated by crossing hGFAP-cre, Hk2f/f and SmoM2 mouse lines. Mice heterozygous for 
hGFAP-cre and SmoM2 alleles develop medulloblastoma with 100% frequency by P12 and 
typically die from tumor progression by P20 [22, 23]. In these mice, cerebellar development 
is profoundly altered as the posterior fossa becomes filled with rapidly growing tumor. 
Tumors with homozygous conditional deletion of Hk2 occurred in hGFAP-
cre;SmoM2;Hk2f/f with similar incidence, but were markedly less malignant. Deletion of 
Hk2 significantly increased median survival from 18 to 30 days and in contrast to the 100% 
mortality of mice with medulloblastoma with intact Hk2, allowed 30% of tumor-bearing 
mice to survive long-term and to breed [9]. Similar survival benefits were demonstrated 
when Hk2 was deleted in mouse models of glioblastoma[24], and more recently, lung and 
breast cancer, confirming the broad relevance of Hk2 to solid tumors beyond developmental 
brain tumors [25].
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Histologic examination of Hk2 deleted medulloblastomas showed that Hk2-deficiency 
dramatically increased the proportion of SmoM2-expressing CGNPs that differentiated 
appropriately, leading to relative normalization of cerebellar architecture. Staining for 
endothelial marker CD31 demonstrated increased vascularization in Hk2-deficient tumors. 
Proliferating cells localized predominantly in the perivascular regions; between regions of 
perivascular proliferation tumor cells exited the cell cycle and up-regulated the 
differentiation marker p27. The increased angiogenesis of Hk2-deficient tumors and the 
increased dependence of proliferative behavior on vascular proximity, suggested that growth 
restriction occurred when these Hk2-deficient tumors exceeded the limits of the 
compensatory effect of neovascularization. The presence of energy scarcity in Hk2-deficient 
tumors was assessed by studies of the phosphorylation of the intracellular energy sensor, 
AMP-activated Kinase (AMPK). Consistent with energy scarcity, in Hk2-deficient tumors 
AMPK was consistently phosphorylated, as was the AMPK target, Acc1 [9].
How does AMPK activation in Hk2-deficient tumors impair malignant growth? As shown in 
Figure 1, the metabolic switch from lipid catabolism to lipid synthesis, identified by Bhatia 
et al as required for tumor growth, [7, 8] may be the underlying mechanism that is targeted 
by AMPK. While Bhatia et al showed that lipogenesis is regulated in CGNPs by E2F1 and 
PPARγ, AMPK-Acc1 signaling has been shown to down-regulate lipid production in diverse 
cell types [26] and may similarly affect the lipid metabolism of CGNPs. AMPK activation in 
Hk2-deletion medulloblastoma increased the inhibitory phosphorylation of Acc1 [9], which 
would be predicted to block lipogenesis by inhibiting production of malonyl-CoA [27], 
leading to increased fatty acid oxidation [28]. Thus lipogenic metabolism may be a key 
mechanism of tumor pathogenesis that is supported by Hk2-dependent glycolysis. By 
preventing AMPK activation, Hk2-mediated aerobic glycolysis may enhance tumor growth 
not only by generating energy with less oxygen, but also by allowing lipogenesis to proceed. 
If so, pharmacologic agents that directly activate AMPK may be able to exploit this 
mechanism to inhibit tumor growth.
The induction of PkM2 by Shh, noted by Bhatia et al may be another critical link between 
Shh-driven glycolysis and Shh-driven lipid synthesis. We have recently found that Smo-
driven medulloblastomas in mice, like CGNPs, up-regulate PkM2 (unpublished data). While 
pyruvate kinase plays an essential role in glucose metabolism, there are key differences in 
the activity of the PkM1 and PkM2 isoforms. In contrast to PkM1, the PkM2 isoform is 
subject to down-regulation of enzymatic activity and this regulation may be essential to its 
growth promoting effect [29]. By poorly catalyzing the conversion of phosphoenolpyruvate 
into pyruvate, PkM2 may increase the supply of glycolytic intermediaries upstream of 
phosphoenolpyruvate that can be diverted into alternative fates, including lipid production 
and nucleotide biosynthesis [30, 31].
The expression of the less active PkM2 isoform rather than the constitutively active PKM1, 
in both Shh-stimulated CGNPS and medulloblastoma suggests that pyruvate kinase activity 
may have an inhibitory effect on growth. Recent work by Anastasiou et al demonstrated that 
PkM2 activators, DASA-58 and TEPP-46, can block lipogenesis and inhibit the growth of 
PkM2-expressing cancers [32]. Unlike the activation of PkM2 by endogenous FBP, the 
activating effect of these agents could not be inhibited by phosphotyrosine signaling. Cells 
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treated with DASA-58 reduced the flux of glucose-derived carbons into acetyl-CoA and 
generally lowered de novo lipid synthesis. Similarly, TEPP-46 treatment reduced the 
intracellular concentrations of acetyl-CoA, lactate, ribose phosphate, and serine, important 
precursors for lipid metabolism. Moreover, xenograft tumors from TEPP-46-treated mice 
recapitulated the metabolic profile found in vitro and exhibited delayed latency and smaller 
size than vehicle-treated mice. These findings show that increasing PkM2 activity alters 
glucose and lipid metabolism and reduces tumor growth. Conversely, Israelsen et al showed 
that conditional deletion of PkM2 actually accelerates tumorigenesis in an in vivo model of 
lymphoma [33]. Within PkM2-deficient tumors, a subpopulation of non-proliferating cells 
expressed PkM1. Proliferative tumor cells, however, expressed no PkM1 and completely 
lacked PkM2. Together these studies show that pyruvate kinase activity correlates inversely 
with malignant growth.
The switch to PkM2 expression in CGNPs may similarly promote neural progenitor growth, 
again demonstrating a developmental origin for a metabolic pattern typically associated with 
cancer. As depicted in Figure 2, in Shh-stimulated CGNPs, low PkM2 activity, operating 
downstream of high Hk-2 driven glycolytic flux, may divert glycolytic intermediates from 
lactate generation, into lipogenesis. PkM2 activation may reduce this diversion of glycolytic 
intermediates, reducing lipid synthesis required for growth. As medulloblastomas up-
regulate PkM2, agents that increase PkM2 enzymatic activity may be able to block the 
lipogenic metabolism of these tumors. Through this mechanism, PkM2 activation, like 
AMPK activation, may offer a novel approach to medulloblastoma therapy by disrupting 
metabolic patterns that support tumor growth.
By up-regulating glycolytic enzymes Hk2 and PkM2, and lipid synthesis enzymes FASN 
and Acc1, while down-regulating lipid catabolizing enzymes including Acox1, Shh 
configures CGNPs for both aerobic glycolysis and lipid synthesis. These processes operate 
in tandem to satisfy the ATP needs of the cell while carrying out a net conversion of glucose 
into lactate and lipids. CGNPs integrate developmental regulation of lipid synthesis and 
aerobic glycolysis in order to support physiological proliferation during brain development. 
These same metabolic patterns become activated in medulloblastoma tumorigenesis and 
function similarly to support malignant growth.
An important question is the relevance of these findings beyond cerebellar development and 
its disruption in medulloblastoma tumorigenesis. Transcriptional analyses of patient-derived 
samples demonstrate that medulloblastoma is a heterogeneous group of tumors, with at least 
4 molecular subtypes [34–38]. The SHH subgroup of medulloblastoma makes up 
approximately 25% of the cases of this rare tumor. Do observations of metabolic regulation 
in cerebellar progenitors and medulloblastoma have relevance for other cell types during 
development and for other cancers?
Rather than being unique to CGNPs, aerobic glycolysis is likely to be a common feature of 
neural progenitors throughout the neuraxis. While Shh-dependent proliferation is unique to 
cerebellar progenitors, Hk1 is absent in all progenitor regions of the postnatal brain [9], 
suggesting a molecular switch to Hk2 may be activated by diverse growth factors. Similarly, 
PkM2 is known to integrate diverse growth factor signaling pathways into a common output 
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of reduced PK activity [39, 40]. Thus the activation of aerobic glycolysis by CGNPs in 
response to Shh may a general response of progenitor cells to the specific growth factors that 
drive them to proliferate. As a group, tumors of neural progenitors, including 
retinoblastoma, Ewing sarcoma and neuroblastoma comprise the largest set of solid tumors 
in children; the set of tumors recapitulating the metabolism of their cells of origin is thus 
likely to be broad.
The role of N-Myc in mediating Shh-induced glycolysis in CGNPs supports the general 
relevance of metabolic configuration to progenitor function. N-Myc, and the homolog C-
Myc, are essential regulators of neural and hematopoietic progenitor function [41, 42]. They 
are also among the common oncogenes activated in human cancer [43, 44], including all 4 
medulloblastoma subtypes [45]. Disruption of Myc-Max interaction in CGNPs treated with 
the inhibitor 10058-F4 blocked the induction of aerobic glycolysis by Shh and prevented 
Shh-induced proliferation [9]. These findings are consistent with the documented role of c-
Myc in up-regulating glycolysis in both normal tissues and in cancer [46, 47]. Moreover, 
disruption of N-Myc-Max interaction with the same agent in neuroblastoma reduced tumor 
growth while altering metabolism [48]. Thus while the metabolic and proliferative behaviors 
induced by Shh may be specific to CGNPs, the pattern of growth factor-induced metabolic 
configuration may be generalizable to diverse progenitors and progenitor-derived cancers. 
N-Myc and C-Myc proteins may be common effectors of metabolic transformation that 
operate downstream of diverse mitogenic signals, typified by Shh, that are cell-type specific.
The phenomenon of postnatal cerebellar neurogenesis degenerating into medulloblastoma in 
mice presents an ideal system in which to study the developmental origins of cancer 
metabolism. Because the cells of origin of these tumors are identifiable and accessible, the 
molecular regulation of energy metabolism in these progenitors can be discerned in detail. 
Moreover, the patterns of metabolism in cells of origin and in resulting tumors can be 
compared. Importantly, Shh-pathway activation drives medulloblastoma tumorigenesis 
through downstream oncogenes, including N-myc, that are relevant to diverse cancers in 
both children and adults. Understanding the mechanisms that regulate the metabolism of 
cerebellar progenitors during development may thus lead to novel, metabolic approaches to 
anti-cancer therapy.
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Shh signaling regulates lipid metabolism and glycolysis in an integrated manner. Regulatory 
genes and effector proteins are denoted by ovals and rounded rectangles, respectively, 
whereas inhibitors are in hexagons. Entities involved in lipid or glucose metabolism are in 
blue or red. AMPK may switch-off lipogenesis when aerobic glycolysis is blocked and 
energy scarcity results.
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By providing variable resistance to glycolytic flux, PkM2, induced by Shh, is ideally 
positioned to divert glycolytic intermediates, generated downstream of Shh-induced Hk2, to 
alternate metabolic pathways, such as lipogenesis, that support developmental and malignant 
growth. A) Low PkM2 activity may channel glycolytic intermediates to alternate fates while 
allowing some production of lactate. B) Hk2 deletion reduces glycolytic flux upstream of 
PkM2, preventing both lactate generation and alternate uses of glycolytic intermediates. C) 
Pharmacologic activation of PkM2 activation may increase lactate generation while acting 
like Hk2 deletion to block the growth-promoting effects of aerobic glycolysis.
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